title: Buprenorphine-induced linear IgA bullous dermatosis "down the rail".
authors.forename: Helene
authors.initials: H
authors.lastname: Pol
authors.forename: Suzanne
authors.initials: S
authors.lastname: Devaux
authors.forename: Emilie
authors.initials: E
authors.lastname: Tournier
authors.forename: Francoise
authors.initials: F
authors.lastname: Fortenfant
authors.forename: Carle
authors.initials: C
authors.lastname: Paul
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001365:Axilla; D001707:Biopsy, Needle; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects*; D004797:Enzyme-Linked Immunosorbent Assay; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D006556:Heroin Dependence / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D006875:Hydrotherapy / Q000379:methods; D007070:Immunoglobulin A / Q000378:metabolism; D007150:Immunohistochemistry; D062027:Linear IgA Bullous Dermatosis / Q000139:chemically induced* / Q000473:pathology* / Q000628:therapy; D008297:Male; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D007070:Immunoglobulin A; D002047:Buprenorphine